Molecular subtypes are prognostic for N3 breast cancer patients in the modern therapeutic era
Rattachement africain : tr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Nodal (N) status and molecular subtypes are well-known prognostic factors for breast cancer patients. The aim of the present study was to evaluate whether there was a prognostic role of molecular subtypes for pN3a breast cancer patients in the modern therapeutic era. The present study retrospectively evaluated a total of 521 breast cancer patients who had 10 or more metastatic lymph nodes and received adjuvant systemic therapy at the Oncology Department of four different centers in Turkey between 2000-2015. Patients were divided into four molecular subtypes by immunohistochemical staining. There were no significant differences in relapse rates according to the molecular subtypes (P=0.07). The five year disease free survival rate was 62% for the whole study population, 67% for Luminal A tumors, 53% for Luminal B tumors, 64% for human epidermal growth factor receptor 2-positive tumors and 56% for triple negative tumors. Luminal A patients had a better progression free survival when compared with Luminal B (P=0.026) and triple negative (P=0.07) patients. pT stage (P<0.001), and breast cancer subtype (P<0.001), remained significant independent factors for disease free survival. Therefore, breast cancer subtypes are still prognostic for patients with pN3 breast cancer.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Molecular subtypes are prognostic for N3 breast cancer patients in the modern therapeutic era
- Date Crossref
- 19/11/2018
- Éditeur
- Spandidos Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Adnan Menderes University Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Dicle University Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi pays non établi dans la noticeÉtablissement de santé
-
Numune Training and Research Hospital Department of Medical Oncology pays non établi dans la noticeÉtablissement de santé
-
Dr L�tfi Kirdar Kartal Training and Research Hospital Department of Medical Oncology pays non établi dans la noticeStructure de recherche
Department of Medical Oncology — Adnan Menderes University, Department of Medical Oncology — Dicle University et Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi, avec 2 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.